Oxurion NV — Board/Management Information 2021

Jul 13, 2021

TOM GRANEY, CFA

Boston, MA, USA ♦ (908) 922-3035 ♦ tomgraney2020@gmail.com

CHIEF EXECUTIVE OFFICER/CHIEF FINANCIAL Officer – Life Sciences

Driven and strategic life science finance executive with over 25 years of successful, diverse and rich experience in biotech/pharma and medical devices/diagnostics. Deep experience in all operational and strategic aspects of company building as corporate CFO at mid cap and large cap public and private companies. Raised >\$500M in public and private financing with a track record as a trusted and clear communicator to investors, analysts and other stakeholders. Extensive experience in all aspects of business development and M&A. Thrived across a range of settings and business conditions; large and profitable companies (>\$10B in revenue, >10k employees) and preclinical start-ups (~70 employees), fast growth and high margin to turnarounds. Expertise in resource and capital allocation and portfolio management. Extensive global experience - lived and worked abroad. Extensive track record of building and developing high performing teams, including >10 former direct reports that are now public company CFOs. Public biotech independent board member, Audit (qualified "Financial Expert") and Compensation and Nominating committees.

PROFESSIONAL EXPERIENCE

Oxurion NV (BRU: OXUR) and Oncurious NV – Leuven, Belgium2020-Present

Oxurion is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders. Oncurious is a preclinical stage biotech company focused on developing innovative oncology treatments that are designed to enhance T cell activity and migration and infiltration into resistant tumor sites, boosting the response to immunotherapy in the large numbers of patients who respond suboptimally to existing treatment.

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Recruited into the organization to sufficiently capitalize and fund the company through clinical development for its lead assets. In addition, there is a focus to increase the capability of the finance and accounting functions to prepare the company to be Nasdaq public ready.

AC Immune SA (NASDAQ: ACIU) – Lausanne, Switzerland 2016-Present

AC Immune is a clinical stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The company currently has six assets in clinical development and has several important collaborations.

INDEPENDENT BOARD MEMBER

Member of Audit and Compensation and Nominating committees. First American on a previously all European Board. The company has since added four more Americans including the current Board Chairman. Provided oversight during the successful remediation of a material weakness in 2016.

Generation Bio – Cambridge MA2019-2020

Generation Bio is a recently public (NASDAQ: GBIO), preclinical, non-viral gene therapy company that was founded by Atlas Venture and raised >\$200m in capital over two years. Crossover investors included T Rowe Price, Farallon, Wellington, Fidelity, Invus, Casdin, Deerfield and Foresite Capital among others.

CHIEF FINANCIAL OFFICER

Recruited into the organization to sufficiently capitalize and fund the company through the beginning of clinical development for the lead assets. In addition, there was a focus to increase the capability of the finance and accounting functions to get the company public ready.

Accomplishments:

• Series C financing (\$110M) attracting enough capital from top tier long-term investors to advance the company's two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-enabling studies and clinical development
• Turned over the entire accounting and finance team, significantly upgrading the talent
• Improved the systems, processes and capabilities of the accounting, finance and strategic sourcing teams to become public company ready

Vertex Pharmaceuticals (NASDAQ: VRTX) – Boston, MA 2017-2019

Vertex is a commercial stage global biotech company with revenues >\$3B that invests in research to create transformative medicines to treat serious diseases. Vertex has four approved medicines.

CHIEF FINANCIAL OFFICER

Responsible for all aspects of Finance and Accounting. Team of >60 associates based in Boston, Europe and Brazil.

Accomplishments

• Led cross functional team in the organizational redesign of the International business unit including the go-to-market model and key support functions.
• Developed capital deployment prioritization strategy resulting in the company's first return of capital program, stock repurchases to offset the dilution from employee equity grants.
• Improved team effectiveness in key areas of decision support including, corporate performance management, valuation, portfolio management and resource allocation.
• Ensured company readiness for the original BREXIT deadline including end to end supply chain, ERP and tax considerations.

Ironwood Pharmaceuticals (NASDAQ: IRWD) – Cambridge, MA 2014-2017

Ironwood is a commercial stage biotech discovering, developing and commercializing products in gastroenterology, rheumatology and primary care.

CHIEF FINANCIAL OFFICER/SVP, CORPORATE STRATEGY

Areas of responsibility included: Finance, Corporate Strategy, Corporate Development, Investor Relations, IT, Corporate Communications, Quality and Supply Chain.

Accomplishments

• Led the successful acquisition and integration of second commercial franchise resulting in a doubling of the sales force and increased commercial capabilities
• Raised \$335M in convertible debt with a call spread, optimizing the capital structure utilizing favorable marginal cost of capital with low risk of dilution
• Restructured \$150M of unsecured debt significantly reducing the cost of capital, extending the duration and maintaining operational flexibility
• Significant upgrades to the capabilities and leadership across the organization

Johnson and Johnson is the world's largest and most broadly-based health care company.

• Led the restructuring of commercial rights in Europe by leveraging US commercial partnership

Johnson & Johnson (NYSE: JNJ) – New Brunswick, NJ 1994-2014

Ethicon Surgical Care, Worldwide VP of Finance, CFO (2012-2014)

Ethicon Surgical Care is a global leader in surgical medical devices: >\$6.5B in revenue, 26 manufacturing sites, >6000 employees.

Accomplishments

• Financial leader of the successful integration of two large J&J affiliates
• Drove significant resource allocation decisions resulting in go-to-market model changes and restructuring, fueling growth in emerging markets and in key growth platforms
• Key role in J&J's first company acquisition in China
• Completed J&J's most selective leadership development program (top 100)
• J&J CFO task force for talent development and succession planning across the enterprise

Ethicon, Inc., Worldwide VP of Finance, CFO (2010-2012)

Ethicon, Inc. is a global leader in surgical medical devices: \$5B in revenue, 23 manufacturing sites, >4000 employees.

Accomplishments

• Leadership role in acquisition and integration of ENT start-up medical device company
• Chaired Global Commercial Leadership Team, thought leadership on commercial strategy
• Delivered financial commitments while improving business health through active innovation and commercialization portfolio management, resulting in accelerated growth

J&J Global Supply Chain, VP of Finance (2009-2010)

Johnson & Johnson enterprise supply chain.

Dedicated finance leader on the design and implementation team that successfully created an enterprise wide supply chain organization. Centralized ~120 manufacturing sites and 50,000 employees under one organization. Created value through standardization, enterprise quality system, increased capacity utilization and plant rationalization/improved capital intensity.

Janssen Pharmaceuticals, VP of Finance, CFO (2008-2009)

North American pharmaceutical business unit (\$10B in revenue and J&J's largest and most profitable business unit). Primary Care and Specialty products for the US and Canada. Therapeutic areas included CNS, GI, Pain, Women's Health, anti-infectives, branded generics etc.

Accomplishments

• Key role in restructuring the commercial model in preparation for major patent expirations
• Portfolio analysis led to differential investments focused on sustainable profitable growth
• Co-leader J&J Value Creation, J&J executive leadership development program (top 300)

Tibotec and Virco, Belgium, Worldwide VP of Finance, CFO (2005-2008)

Fully integrated global virology business including diagnostics. Company advanced from clinical stage to commercial stage and became J&J's fastest growing business unit, from zero to >\$1B.

Accomplishments

• Led BD negotiations for Hepatitis C assets and HIV fixed dose combination transactions
• Drove R&D portfolio optimization and pricing and reimbursement negotiations in HIV
• Instrumental in the development of commercial organization and capabilities

J&J Pharmaceutical Strategic Marketing (PGSM), Exec Dir, Strategic Marketing Virology (2005)

PGSM is responsible for asset development, life-cycle management and regulatory strategies.

Accomplishments

• Key role in developing a patient access strategy for HIV products in emerging markets
• Compound development champion for tuberculosis drug. It became the first targeted TB drug with a novel mechanism of action to be approved in more than 40 years.
• Signed landmark third party market access manufacturing agreement in South Africa

Janssen-Cilag (UK), England, Area Finance Director/CFO (2003-2005)

Janssen-Cilag is the pharmaceutical sales and marketing business unit for the UK, Ireland and sub-Saharan Africa.

Accomplishments

• Successful negotiations of product pricing with NHS in England, Scotland and Wales
• Multiple licensing transactions
• Integration of the UK R&D site and the commercial site, improving leverage and cost structure

Janssen Pharmaceuticals, Commercial Controller (2001-2003)

US pharmaceutical business (\$3.0B), \$900M in commercial and clinical trial investments.

Accomplishments

• Leadership role in strategy development for two value creating field force expansions
• Development portfolio optimization analysis driving significant marketing mix changes
• Evaluated numerous in-license opportunities across a range of therapeutic areas

J&J, Mergers & Acquisitions, Project Director (1998-2001)

Corporate M&A team evaluating acquisition/divestiture opportunities in medtech, pharma and consumer sectors. Scope: valuation, due diligence, negotiation strategy, deal structure and integration.

Accomplishments

• Key member of corporate venture arm of J&J (JJDC)
• Led >40 acquisition valuations in excess of \$100B
• Developed standardized methodology for valuing assets in development and commercial assets
• Drove the J&J enterprise financing plan and long-range capital structure strategy

Ethicon Gynecare Division, Integration Leader and Finance Manager (1996-1998) Ethicon, Inc., Licensing and Acquisition Analysis, Finance Manager (1995-1996) Ethicon, Inc., Financial Accounting Senior Analyst (1994-1995)

Various Roles in Banking 1987-1994

Vista Bancorp, Assistant Vice President/Chief Investment Officer (1990-1994) Barnett Bank, Accounting and Treasury Supervisor (1989-1990) Chemical Bank, General Accounting Supervisor (1987-1989)

EDUCATION

Thomas Jefferson University, Jefferson School of Population Health Coursework toward Masters in Public Health (2008-2009, withdrew due to relocation)

New York University, Leonard N. Stern School of Business

MBA, Triple major in Marketing, Finance and International Business, 1999

University of Delaware

BS, Accounting, 1987

PROFESSORSHIP

New York University, Department of Finance, Law and Taxation Adjunct Professor, Mergers and Acquisitions, 6/99 - 12/01

PROFESSIONAL CERTIFICATIONS

Chartered Financial Analyst (CFA) 2001 Certified Financial Manager (CFM) 1996 Certified Management Accountant (CMA) 1994